BioE PhD Defense Presentation- Rebecca Schneider

*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************

Event Details
  • Date/Time:
    • Tuesday February 28, 2023
      9:00 am - 11:00 am
  • Location: 1128 IBB and https://gatech.zoom.us/j/97953677766
  • Phone:
  • URL:
  • Email:
  • Fee(s):
    N/A
  • Extras:
Contact
No contact information submitted.
Summaries

Summary Sentence: "High-throughput 3D on-chip potency assay for improved cell therapy product clinical prediction"

Full Summary: BioE PhD Defense Presentation- "High-throughput 3D on-chip potency assay for improved cell therapy product clinical prediction" -Rebecca Schneider

Advisor: 

Andrés J. García, PhD (Georgia Institute of Technology)

 

Committee Members:

John Blazeck, PhD (Georgia Institute of Technology)

Wilbur A. Lam, MD, PhD (Emory University and Georgia Institute of Technology)

Ankur Singh, PhD (Georgia Institute of Technology)

Ross Marklein, PhD (University of Georgia)

 

High-throughput 3D on-chip potency assay for improved cell therapy product clinical prediction

 

Cell therapies offer promising strategies to treat diverse oncologic, inflammatory, and immune applications. Despite promising early phase clinical data, cell therapy candidates face new translational challenges, in part, due to a poor understanding of the cell therapy product during drug development and scale up. Current potency testing is often overly simplified and strongly biased by traditional 2D culture techniques. By engineering improved, well-defined, physiological-relevant in vitro systems, we aim to provide high-throughput and reproducible potency assays with improved outcome prediction of in vivo and/or clinical response. We have demonstrated proof-of-concept of the on-chip platform by showing improved in vitro immunomodulatory prediction and stronger fidelity to in vivo secretion compared to traditional 2D culture for n=9 mesenchymal stem/stromal cell (MSC) donors. We have further evaluated n=60 MSC and MSC-derivative clinical samples using the on-chip platform and found secretion outcomes with greater correlation and/or variance across donor-matched characteristics compared to 2D culture secretion. Future work will include platform clinical validation by evaluation of on-chip secretion correlation to patient-matched outcomes. The data presented here is in strong support of the value of the on-chip system to deliver scalable and high throughput cell product secretion information more predictive of in vivo and/or clinical settings.

Additional Information

In Campus Calendar
No
Groups

Bioengineering Graduate Program

Invited Audience
Faculty/Staff, Public, Undergraduate students
Categories
Career/Professional development
Keywords
go-BioE
Status
  • Created By: Laura Paige
  • Workflow Status: Published
  • Created On: Feb 14, 2023 - 10:08am
  • Last Updated: Feb 14, 2023 - 10:08am